Linked Data API

Show Search Form

Search Results

852479
star this property registered interest false more like this
star this property date less than 2018-02-28more like thismore than 2018-02-28
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Rare Diseases: Medical Treatments Abroad more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of access to specialist cross-border healthcare for sufferers of rare diseases following Brexit; and how they plan to ensure that those patients continue to benefit from specialist medical expertise across EU member states following Brexit. more like this
star this property tabling member printed
Lord Taylor of Warwick more like this
star this property uin HL5962 remove filter
star this property answer
answer
unstar this property is ministerial correction false remove filter
unstar this property date of answer less than 2018-03-13more like thismore than 2018-03-13
star this property answer text <p>The United Kingdom Government has made clear that it wishes to see the existing reciprocal healthcare arrangements with the European Union continued after the UK leaves the EU. All UK-insured residents, including sufferers of rare diseases, benefit from the reciprocal healthcare arrangements currently in place and the Government is working to ensure this access to healthcare in EU member states continues on the same terms as they do now after the UK leaves the European Union.</p><p>During negotiations with the EU on the Withdrawal Agreement, the UK has therefore been seeking to protect the healthcare arrangements currently set out in EU Regulations 883/2004 and 987/2009. In the meantime, while the UK remains a member of the EU, it will continue to respect the rights and honour the obligations of EU membership and so the current arrangements remain in place.</p><p>The UK is recognised internationally for its expertise and excellence in the field of rare diseases. In this regard, the UK Government has three key principles in its approach to the development of a post-Exit relationship with the EU:</p><p>- That no patient should be disadvantaged;</p><p>- That the UK should continue to play a leading role promoting and ensuring public health, both in Europe and around the world; and</p><p>- Industry must be able to get their products into the UK market as quickly and simply as possible, with the UK and Europe at the forefront of medical innovation.</p><p> </p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-03-13T15:51:47.64Zmore like thismore than 2018-03-13T15:51:47.64Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1796
unstar this property label Biography information for Lord Taylor of Warwick more like this